Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009 Aug;33(8):1144-6

Date

04/28/2009

Pubmed ID

19394693

DOI

10.1016/j.leukres.2009.03.011

Scopus ID

2-s2.0-67349165083   27 Citations

Abstract

ETV6/ABL is a rare gene rearrangement that has rarely been detected in Philadelphia-negative chronic myeloproliferative disorders (C-MPD) and found to have tyrosine kinase activity similar to the BCR/ABL fusion protein. We describe a case of a 61-year-old female with a C-MPD associated with an ETV6/ABL gene rearrangement. She achieved complete cytogenetic remission on imatinib 400mg daily for 17 months, but then developed morphologic and cytogenetic relapse. After starting nilotinib 400mg orally twice daily, she achieved CCyR at 3, 6, and 11 months, suggesting that second-generation TKIs can result in favorable responses in patients with ETV6/ABL rearrangement who relapse after imatinib.

Author List

Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E

Authors

Ehab L. Atallah MD Professor in the Medicine department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Benzamides
Eosinophilia
Female
Gene Rearrangement
Humans
Imatinib Mesylate
Middle Aged
Myeloproliferative Disorders
Oncogene Proteins, Fusion
Piperazines
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Pyrimidines
Remission Induction